Comparison of clinical outcomes of BRCA1/2 pathologic mutation, variants of unknown significance, or wild type epithelial ovarian cancer patients

Kyung Jin Eoh, Hyung Seok Park, Ji Soo Park, Seung Tae Lee, Jeongwoo Han, Jung Yun Lee, Sang Wun Kim, Sunghoon Kim, Young Tae Kim, Eun Ji Nam

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose The purpose of this study was to investigate the clinical features of epithelial ovarian cancer (EOC) patients according to BRCA1/2 mutation status (mutation, variant of uncertain significance [VUS], or wild type). Materials and Methods We analyzed 116 patients whose BRCA1/2 genetic test results were available for mutation type and clinical features, including progression-free survival (PFS), overall survival (OS), and response rate. These characteristics were compared according to BRCA1/2 mutation status. Results Thirty-seven (37/116, 31.9%) BRCA1/2mutations were identified (BRCA1, 30; BRCA2, 7). Mutation of c.3627_3628insA (p.Leu1209_Glu1210?fs) in BRCA1 was observed in five patients (5/37, 13.5%). Twenty-five patients had BRCA1/2 VUSs (25/116, 21.6%). Personal histories of breast cancer were observed in 48.6% of patients with BRCA1/2 mutation (18/37), 16.0% of patients with BRCA1/2 VUS (4/25), and 7.4% of patients with BRCA wild type (4/54) (p < 0.001). Patients with BRCA1/2 mutation showed longer OS than those with BRCA1/2 wild type (p=0.005). No significant differences were detected in PFS, OS, or response rates between patients with BRCA1/2 VUS and BRCA1/2 mutation (p=0.772, p=0.459, and p=0.898, respectively). Conclusion Patients with BRCA1/2mutation had longer OS than those with BRCA1/2wild type. Patients with BRCA1/2 mutation and BRCA1/2 VUS displayed similar prognoses.

Original languageEnglish
Pages (from-to)408-415
Number of pages8
JournalCancer Research and Treatment
Volume49
Issue number2
DOIs
Publication statusPublished - 2017 Apr 1

Fingerprint

Mutation
Disease-Free Survival
Survival
Ovarian epithelial cancer
Survival Rate
Breast Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Eoh, Kyung Jin ; Park, Hyung Seok ; Park, Ji Soo ; Lee, Seung Tae ; Han, Jeongwoo ; Lee, Jung Yun ; Kim, Sang Wun ; Kim, Sunghoon ; Kim, Young Tae ; Nam, Eun Ji. / Comparison of clinical outcomes of BRCA1/2 pathologic mutation, variants of unknown significance, or wild type epithelial ovarian cancer patients. In: Cancer Research and Treatment. 2017 ; Vol. 49, No. 2. pp. 408-415.
@article{ecd245352acb4eeab25e2c2c8662b2d9,
title = "Comparison of clinical outcomes of BRCA1/2 pathologic mutation, variants of unknown significance, or wild type epithelial ovarian cancer patients",
abstract = "Purpose The purpose of this study was to investigate the clinical features of epithelial ovarian cancer (EOC) patients according to BRCA1/2 mutation status (mutation, variant of uncertain significance [VUS], or wild type). Materials and Methods We analyzed 116 patients whose BRCA1/2 genetic test results were available for mutation type and clinical features, including progression-free survival (PFS), overall survival (OS), and response rate. These characteristics were compared according to BRCA1/2 mutation status. Results Thirty-seven (37/116, 31.9{\%}) BRCA1/2mutations were identified (BRCA1, 30; BRCA2, 7). Mutation of c.3627_3628insA (p.Leu1209_Glu1210?fs) in BRCA1 was observed in five patients (5/37, 13.5{\%}). Twenty-five patients had BRCA1/2 VUSs (25/116, 21.6{\%}). Personal histories of breast cancer were observed in 48.6{\%} of patients with BRCA1/2 mutation (18/37), 16.0{\%} of patients with BRCA1/2 VUS (4/25), and 7.4{\%} of patients with BRCA wild type (4/54) (p < 0.001). Patients with BRCA1/2 mutation showed longer OS than those with BRCA1/2 wild type (p=0.005). No significant differences were detected in PFS, OS, or response rates between patients with BRCA1/2 VUS and BRCA1/2 mutation (p=0.772, p=0.459, and p=0.898, respectively). Conclusion Patients with BRCA1/2mutation had longer OS than those with BRCA1/2wild type. Patients with BRCA1/2 mutation and BRCA1/2 VUS displayed similar prognoses.",
author = "Eoh, {Kyung Jin} and Park, {Hyung Seok} and Park, {Ji Soo} and Lee, {Seung Tae} and Jeongwoo Han and Lee, {Jung Yun} and Kim, {Sang Wun} and Sunghoon Kim and Kim, {Young Tae} and Nam, {Eun Ji}",
year = "2017",
month = "4",
day = "1",
doi = "10.4143/crt.2016.135",
language = "English",
volume = "49",
pages = "408--415",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "2",

}

Comparison of clinical outcomes of BRCA1/2 pathologic mutation, variants of unknown significance, or wild type epithelial ovarian cancer patients. / Eoh, Kyung Jin; Park, Hyung Seok; Park, Ji Soo; Lee, Seung Tae; Han, Jeongwoo; Lee, Jung Yun; Kim, Sang Wun; Kim, Sunghoon; Kim, Young Tae; Nam, Eun Ji.

In: Cancer Research and Treatment, Vol. 49, No. 2, 01.04.2017, p. 408-415.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of clinical outcomes of BRCA1/2 pathologic mutation, variants of unknown significance, or wild type epithelial ovarian cancer patients

AU - Eoh, Kyung Jin

AU - Park, Hyung Seok

AU - Park, Ji Soo

AU - Lee, Seung Tae

AU - Han, Jeongwoo

AU - Lee, Jung Yun

AU - Kim, Sang Wun

AU - Kim, Sunghoon

AU - Kim, Young Tae

AU - Nam, Eun Ji

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Purpose The purpose of this study was to investigate the clinical features of epithelial ovarian cancer (EOC) patients according to BRCA1/2 mutation status (mutation, variant of uncertain significance [VUS], or wild type). Materials and Methods We analyzed 116 patients whose BRCA1/2 genetic test results were available for mutation type and clinical features, including progression-free survival (PFS), overall survival (OS), and response rate. These characteristics were compared according to BRCA1/2 mutation status. Results Thirty-seven (37/116, 31.9%) BRCA1/2mutations were identified (BRCA1, 30; BRCA2, 7). Mutation of c.3627_3628insA (p.Leu1209_Glu1210?fs) in BRCA1 was observed in five patients (5/37, 13.5%). Twenty-five patients had BRCA1/2 VUSs (25/116, 21.6%). Personal histories of breast cancer were observed in 48.6% of patients with BRCA1/2 mutation (18/37), 16.0% of patients with BRCA1/2 VUS (4/25), and 7.4% of patients with BRCA wild type (4/54) (p < 0.001). Patients with BRCA1/2 mutation showed longer OS than those with BRCA1/2 wild type (p=0.005). No significant differences were detected in PFS, OS, or response rates between patients with BRCA1/2 VUS and BRCA1/2 mutation (p=0.772, p=0.459, and p=0.898, respectively). Conclusion Patients with BRCA1/2mutation had longer OS than those with BRCA1/2wild type. Patients with BRCA1/2 mutation and BRCA1/2 VUS displayed similar prognoses.

AB - Purpose The purpose of this study was to investigate the clinical features of epithelial ovarian cancer (EOC) patients according to BRCA1/2 mutation status (mutation, variant of uncertain significance [VUS], or wild type). Materials and Methods We analyzed 116 patients whose BRCA1/2 genetic test results were available for mutation type and clinical features, including progression-free survival (PFS), overall survival (OS), and response rate. These characteristics were compared according to BRCA1/2 mutation status. Results Thirty-seven (37/116, 31.9%) BRCA1/2mutations were identified (BRCA1, 30; BRCA2, 7). Mutation of c.3627_3628insA (p.Leu1209_Glu1210?fs) in BRCA1 was observed in five patients (5/37, 13.5%). Twenty-five patients had BRCA1/2 VUSs (25/116, 21.6%). Personal histories of breast cancer were observed in 48.6% of patients with BRCA1/2 mutation (18/37), 16.0% of patients with BRCA1/2 VUS (4/25), and 7.4% of patients with BRCA wild type (4/54) (p < 0.001). Patients with BRCA1/2 mutation showed longer OS than those with BRCA1/2 wild type (p=0.005). No significant differences were detected in PFS, OS, or response rates between patients with BRCA1/2 VUS and BRCA1/2 mutation (p=0.772, p=0.459, and p=0.898, respectively). Conclusion Patients with BRCA1/2mutation had longer OS than those with BRCA1/2wild type. Patients with BRCA1/2 mutation and BRCA1/2 VUS displayed similar prognoses.

UR - http://www.scopus.com/inward/record.url?scp=85017380482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017380482&partnerID=8YFLogxK

U2 - 10.4143/crt.2016.135

DO - 10.4143/crt.2016.135

M3 - Article

C2 - 27488874

AN - SCOPUS:85017380482

VL - 49

SP - 408

EP - 415

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 2

ER -